A new ultrasound imaging system for early detection of breast cancer
B7-H3 Targeted Ultrasound Molecular Imaging System for Early Breast Cancer and Metastatic Detection
This study is testing a new ultrasound method that uses special bubbles to help find breast cancer earlier and more accurately, especially for women with dense breast tissue, making it easier for doctors to diagnose and treat.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11093921 on NIH RePORTER |
What this research studies
This research focuses on developing an advanced ultrasound molecular imaging system that uses targeted contrast microbubbles to detect breast cancer at an early stage. By binding to specific proteins found in breast tumors, this innovative technique aims to improve the accuracy of breast cancer diagnosis, especially in women with dense breast tissue. The system is designed to integrate seamlessly with existing ultrasound technology, making it accessible for use in breast imaging clinics. The goal is to enhance the noninvasive characterization of breast lesions and ultimately improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are women with dense breast tissue who are at risk for breast cancer.
Not a fit: Patients with non-dense breast tissue or those who have already been diagnosed with advanced breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of breast cancer, significantly improving survival rates.
How similar studies have performed: Previous research has shown promise in using targeted ultrasound imaging techniques for cancer detection, indicating that this approach could be effective.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Dahl, Jeremy — Stanford University
- Study coordinator: Dahl, Jeremy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.